Jillian Clare Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jillian Clare Cohen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Heather Boon
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
1 shared publication - Hina Laeeque
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
1 shared publication - Joseph D'Cruz
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
1 shared publication L Hawkins
Lead Health Specialist, The World Bank Washington DC
1 shared publication- Laura C Esmail
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada
1 shared publication M Mrazek
Economist (Health), The World Bank Washington DC
1 shared publication
Latest Publications
- Open Access
- 31 July 2007
- Published by Springer Nature in Human Resources for Health
- Vol. 5 (1) , 20
Human resource management in the Georgian National Immunization Program: a baseline assessment
Georgia's health care system underwent dramatic reform after gaining independence in 1991. The decentralization of the health care system was one of the core elements of health care reform but reports suggest that human resource management issues were overlooked. The Georgian national immunization program was affected by these reforms and is not functioning at optimum levels. This paper describes the state of human resource management practices within the Georgian national immunization program in late 2004.
- 31 July 2007
- Published by Springer Nature in Human Resources for Health
- Vol. 5 (1) , 20
Open AccessHuman resource management in the Georgian National Immunization Program: a baseline assessment
Georgia's health care system underwent dramatic reform after gaining independence in 1991. The decentralization of the health care system was one of the core elements of health care reform but reports suggest that human resource management issues were overlooked. The Georgian national immunization program was affected by these reforms and is not functioning at optimum levels. This paper describes the state of human resource management practices within the Georgian national immunization program in late 2004.
- 24 January 2007
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 81 (3) , 445-449
Tackling Corruption in the Pharmaceutical Systems Worldwide with Courage and Conviction
Poor drug access continues to be one of the main global health problems. Global inequalities in access to pharmaceuticals are caused by a number of variables including poverty, high drug prices, poor health infrastructure, and fraud and corruption--the latter being the subject of this article. There is growing recognition among policy makers that corruption in the pharmaceutical system can waste valuable resources allocated to pharmaceutical products and services. This, in turn, denies those most in need from life-saving or life-enhancing medicines. As a result, international organizations, including the World Health Organization and the World Bank are beginning to address the issue of corruption in the health sector broadly and the pharmaceutical system specifically. This is encouraging news for improving drug access for the global poor who are most harmed by corruption as they tend to purchase less expensive drugs from unqualified or illegal drug sellers selling counterfeit or sub-standard drugs. In our paper, we illuminate what are the core issues that relate to corruption in the pharmaceutical sector. We argue that corruption in the pharmaceutical system can be detrimental to a country's ability to improve the health of its population. Moreover, unless policy makers deal with the issue of corruption, funding allocated to the pharmaceutical system to treat health conditions may simply be wasted and the inequality between rich and poor in access to health and pharmaceutical products will be aggravated.
- 24 January 2007
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 81 (3) , 445-449
Tackling Corruption in the Pharmaceutical Systems Worldwide with Courage and Conviction
Poor drug access continues to be one of the main global health problems. Global inequalities in access to pharmaceuticals are caused by a number of variables including poverty, high drug prices, poor health infrastructure, and fraud and corruption--the latter being the subject of this article. There is growing recognition among policy makers that corruption in the pharmaceutical system can waste valuable resources allocated to pharmaceutical products and services. This, in turn, denies those most in need from life-saving or life-enhancing medicines. As a result, international organizations, including the World Health Organization and the World Bank are beginning to address the issue of corruption in the health sector broadly and the pharmaceutical system specifically. This is encouraging news for improving drug access for the global poor who are most harmed by corruption as they tend to purchase less expensive drugs from unqualified or illegal drug sellers selling counterfeit or sub-standard drugs. In our paper, we illuminate what are the core issues that relate to corruption in the pharmaceutical sector. We argue that corruption in the pharmaceutical system can be detrimental to a country's ability to improve the health of its population. Moreover, unless policy makers deal with the issue of corruption, funding allocated to the pharmaceutical system to treat health conditions may simply be wasted and the inequality between rich and poor in access to health and pharmaceutical products will be aggravated.
- Open Access
- 1 December 2006
- Published by Springer Nature in BMC Health Services Research
- Vol. 6 (1) , 63
The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors
The use of natural health products, such as vitamins, minerals, and herbs, by Canadians has been increasing with time. As a result of consumer concern about the quality of these products, the Canadian Department of Health created the Natural Health Products (NHP) Regulations. The new Canadian regulations raise questions about whether and how the NHP industry will be able to comply and what impact they will have on market structure. The objectives of this study were to explore who in the interview sample is complying with Canada's new NHP Regulations (i.e., submitted product licensing applications on time); and explore the factors that affect regulatory compliance. Twenty key informant interviews were conducted with employees of the NHP industry. The structured interviews focused on the level of satisfaction with the Regulations and perceptions of compliance and non-compliance. Interviews were tape recorded and then transcribed verbatim. Data were independently coded, using qualitative content analysis. Team meetings were held after every three to four interviews to discuss emerging themes. The major finding of this study is that most (17 out of 20) companies interviewed were beginning to comply with the new regulatory regime. The factors that contribute to likelihood of regulatory compliance were: perceptions and knowledge of the regulations and business size. The Canadian case can be instructive for other countries seeking to implement regulatory standards for natural health products. An unintended consequence of the Canadian NHP regulations may be the exit of smaller firms, leading to industry consolidation.
- 1 December 2006
- Published by Springer Nature in BMC Health Services Research
- Vol. 6 (1) , 63
Open AccessThe Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors
The use of natural health products, such as vitamins, minerals, and herbs, by Canadians has been increasing with time. As a result of consumer concern about the quality of these products, the Canadian Department of Health created the Natural Health Products (NHP) Regulations. The new Canadian regulations raise questions about whether and how the NHP industry will be able to comply and what impact they will have on market structure. The objectives of this study were to explore who in the interview sample is complying with Canada's new NHP Regulations (i.e., submitted product licensing applications on time); and explore the factors that affect regulatory compliance. Twenty key informant interviews were conducted with employees of the NHP industry. The structured interviews focused on the level of satisfaction with the Regulations and perceptions of compliance and non-compliance. Interviews were tape recorded and then transcribed verbatim. Data were independently coded, using qualitative content analysis. Team meetings were held after every three to four interviews to discuss emerging themes. The major finding of this study is that most (17 out of 20) companies interviewed were beginning to comply with the new regulatory regime. The factors that contribute to likelihood of regulatory compliance were: perceptions and knowledge of the regulations and business size. The Canadian case can be instructive for other countries seeking to implement regulatory standards for natural health products. An unintended consequence of the Canadian NHP regulations may be the exit of smaller firms, leading to industry consolidation.
- 1 November 2006
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 97 (6) , I15-I18
Expanding Drug Access in Brazil
This paper discusses Brazil’s efforts to provide essential medicines for its population while meeting international trade obligations. In the 1950s and 1960s, Brazil’s pharmaceutical industry was largely overtaken by foreign companies. To counteract this, Brazil enacted a law in 1971 that allowed the production of patented drugs in order to provide affordable medicines, encourage research and development, and reduce dependency on imports. Eventually, pressure from the United States government (through tariffs and sanctions) drove Brazil to introduce pharmaceutical patent laws. Local interests prevailed, however, through Brazil’s liberal interpretation of the TRIPS Agreement, which included a provision that pharmaceutical products must be “worked” or manufactured locally or the government could turn to the use of compulsory licensing. Brazil’s willingness to use the threat of compulsory licensing compelled drug companies to lower HIV/AIDS drug prices substantially. Finally, the paper discusses how Canada can facilitate improving drug access in Latin America through helping Brazil expand its role as a manufacturer and providing medicines to countries without manufacturing capabilities. Cet article porte sur les efforts du Brésil pour offrir des médicaments essentiels à sa population tout en respectant ses obligations commerciales internationales. Durant les années 1950 et 1960, l’industrie pharmaceutique brésilienne a été en grande partie supplantée par des sociétés étrangères. Pour contrer ce mouvement, le Brésil votait en 1971 une loi autorisant la fabrication de médicaments brevetés afin d’offrir à la population des médicaments à prix abordable, d’encourager la recherche-développement et de réduire la dépendance du pays envers les importations. Par la suite, sous la pression du gouvernement des États-Unis (qui avait imposé des droits de douane et des sanctions), le Brésil déposait un ensemble de projets de loi sur les brevets pharmaceutiques. Les intérêts locaux eurent cependant préséance en raison de l’interprétation libérale, par le Brésil, de l’Accord sur les ADPIC (aspects des droits de propriété intellectuelle touchant au commerce), dont l’une des clauses prévoit que les produits pharmaceutiques doivent être «exploités» ou fabriqués localement sans quoi le gouvernement peut recourir aux licences obligatoires. La volonté manifestée par le Brésil de se prévaloir de cette clause a astreint les compagnies pharmaceutiques à réduire considérablement le prix de leurs médicaments contre le VIH et le sida. À la fin de l’article, il est question des moyens pour le Canada de faciliter l’accès aux médicaments en Amérique latine en aidant le Brésil à développer ses capacités de fabrication et à approvisionner en médicaments les pays qui n’ont pas d’industrie pharmaceutique.
- 1 November 2006
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 97 (6) , I15-I18
Expanding Drug Access in Brazil
This paper discusses Brazil’s efforts to provide essential medicines for its population while meeting international trade obligations. In the 1950s and 1960s, Brazil’s pharmaceutical industry was largely overtaken by foreign companies. To counteract this, Brazil enacted a law in 1971 that allowed the production of patented drugs in order to provide affordable medicines, encourage research and development, and reduce dependency on imports. Eventually, pressure from the United States government (through tariffs and sanctions) drove Brazil to introduce pharmaceutical patent laws. Local interests prevailed, however, through Brazil’s liberal interpretation of the TRIPS Agreement, which included a provision that pharmaceutical products must be “worked” or manufactured locally or the government could turn to the use of compulsory licensing. Brazil’s willingness to use the threat of compulsory licensing compelled drug companies to lower HIV/AIDS drug prices substantially. Finally, the paper discusses how Canada can facilitate improving drug access in Latin America through helping Brazil expand its role as a manufacturer and providing medicines to countries without manufacturing capabilities. Cet article porte sur les efforts du Brésil pour offrir des médicaments essentiels à sa population tout en respectant ses obligations commerciales internationales. Durant les années 1950 et 1960, l’industrie pharmaceutique brésilienne a été en grande partie supplantée par des sociétés étrangères. Pour contrer ce mouvement, le Brésil votait en 1971 une loi autorisant la fabrication de médicaments brevetés afin d’offrir à la population des médicaments à prix abordable, d’encourager la recherche-développement et de réduire la dépendance du pays envers les importations. Par la suite, sous la pression du gouvernement des États-Unis (qui avait imposé des droits de douane et des sanctions), le Brésil déposait un ensemble de projets de loi sur les brevets pharmaceutiques. Les intérêts locaux eurent cependant préséance en raison de l’interprétation libérale, par le Brésil, de l’Accord sur les ADPIC (aspects des droits de propriété intellectuelle touchant au commerce), dont l’une des clauses prévoit que les produits pharmaceutiques doivent être «exploités» ou fabriqués localement sans quoi le gouvernement peut recourir aux licences obligatoires. La volonté manifestée par le Brésil de se prévaloir de cette clause a astreint les compagnies pharmaceutiques à réduire considérablement le prix de leurs médicaments contre le VIH et le sida. À la fin de l’article, il est question des moyens pour le Canada de faciliter l’accès aux médicaments en Amérique latine en aidant le Brésil à développer ses capacités de fabrication et à approvisionner en médicaments les pays qui n’ont pas d’industrie pharmaceutique.
- 1 January 2004
- Published by Taylor & Francis in Journal of Pharmaceutical Marketing & Management
- Vol. 16 (3) , 5-11
The Menace or Blessing of Internet Pharmacy? Some Public Policy Considerations
Cross-border pharmaceutical purchasing represents a challenge to accepted practices of pharmacy and the integrity of pharmacy rules and regulations within jurisdictions. This debate affects both the Canadian and American public, as well as their national governments, public and professional advocacy groups, and the pharmaceutical industry itself. It is still unclear as to who really benefits from cross-border Internet pharmacies, but it is clear that this debate has forced regulatory bodies to reengage in policy making and to discuss important issues such as access to medicine and the pharmaceutical system as a whole.
- 1 January 2004
- Published by Taylor & Francis in Journal of Pharmaceutical Marketing & Management
- Vol. 16 (3) , 5-11
The Menace or Blessing of Internet Pharmacy? Some Public Policy Considerations
Cross-border pharmaceutical purchasing represents a challenge to accepted practices of pharmacy and the integrity of pharmacy rules and regulations within jurisdictions. This debate affects both the Canadian and American public, as well as their national governments, public and professional advocacy groups, and the pharmaceutical industry itself. It is still unclear as to who really benefits from cross-border Internet pharmacies, but it is clear that this debate has forced regulatory bodies to reengage in policy making and to discuss important issues such as access to medicine and the pharmaceutical system as a whole.
- 8 April 2003
- Published by Wiley in Developing World Bioethics
- Vol. 3 (1) , 27-48
The Dilemma of Intellectual Property Rights for Pharmaceuticals: The Tension Between Ensuring Access of the Poor to Medicines and Committing to International Agreements
In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for research and development of innovative medicines and ensuring access of the poor to medicine. Fourth, we evaluate these solutions on the basis of utilitarian considerations and urge that equitable pricing is morally preferable to the other solutions.
- 8 April 2003
- Published by Wiley in Developing World Bioethics
- Vol. 3 (1) , 27-48
The Dilemma of Intellectual Property Rights for Pharmaceuticals: The Tension Between Ensuring Access of the Poor to Medicines and Committing to International Agreements
In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for research and development of innovative medicines and ensuring access of the poor to medicine. Fourth, we evaluate these solutions on the basis of utilitarian considerations and urge that equitable pricing is morally preferable to the other solutions.